Everest Medicines Limited (FRA:6HN)

Market Cap	1.41B -34.1%
Revenue (ttm)	207.82M +141.5%
Net Income	-36.26M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	77.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	3.920
Previous Close	3.980
Day's Range	3.920 - 3.920
52-Week Range	3.460 - 8.250
Beta	n/a
RSI	46.26
Earnings Date	Mar 26, 2026

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 812
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6HN

Financial Performance

In 2025, Everest Medicines's revenue was 1.71 billion, an increase of 141.51% compared to the previous year's 706.68 million. Losses were -297.77 million, -71.41% less than in 2024.

Financial numbers in CNY